Jan Smith - Revolution Medicines Chief Officer
| RVMD Stock | USD 57.08 0.30 0.53% |
Executive
Jan Smith is Chief Officer of Revolution Medicines
| Address | 700 Saginaw Drive, Redwood City, CA, United States, 94063 |
| Phone | 650 481 6801 |
| Web | https://www.revmed.com |
Revolution Medicines Management Efficiency
The company has return on total asset (ROA) of (0.2856) % which means that it has lost $0.2856 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4718) %, meaning that it created substantial loss on money invested by shareholders. Revolution Medicines' management efficiency ratios could be used to measure how well Revolution Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.27. At present, Revolution Medicines' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 10.6 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Theresa Lavallee | Coherus BioSciences | 58 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Jeffrey Cole | Cadrenal Therapeutics, Common | N/A | |
| Paul Reider | Coherus BioSciences | 54 | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Vladimir Vexler | Coherus BioSciences | 66 | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| MRCP MD | Coherus BioSciences | 55 | |
| Scott Saywell | Coherus BioSciences | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Richard MD | Lyra Therapeutics | 61 | |
| Michael Chen | Coherus BioSciences | N/A | |
| Cheston Turbyfill | Coherus BioSciences | N/A | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 |
Revolution Medicines Leadership Team
Elected by the shareholders, the Revolution Medicines' board of directors comprises two types of representatives: Revolution Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revolution. The board's role is to monitor Revolution Medicines' management team and ensure that shareholders' interests are well served. Revolution Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revolution Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Pompliano, Founding Officer | ||
| Jack Anders, Chief Officer | ||
| Walter Reiher, Chief Officer | ||
| Mark Goldsmith, President CEO | ||
| Path FRCP, Pres RD | ||
| Margaret JD, Chief Officer | ||
| Michael Fischbach, Academic Board | ||
| Xiaolin Wang, Executive Development | ||
| Kevan Shokat, Academic Board | ||
| Jan Smith, Chief Officer |
Revolution Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revolution Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (845.95) % | ||||
| Current Valuation | 8.09 B | ||||
| Shares Outstanding | 168.22 M | ||||
| Shares Owned By Insiders | 2.13 % | ||||
| Shares Owned By Institutions | 97.87 % | ||||
| Number Of Shares Shorted | 18.14 M | ||||
| Price To Book | 6.10 X | ||||
| Price To Sales | 12,873 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revolution Medicines is a strong investment it is important to analyze Revolution Medicines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revolution Medicines' future performance. For an informed investment choice regarding Revolution Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.005 | Quarterly Revenue Growth (0.95) | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.